Ocular Surface Diseases and Beyond
Leveraging our nicotinic acetylcholine receptor (nAChR) domain expertise, we are focused on the development of OC-01 for the treatment of signs and symptoms of Dry Eye Disease (DED), as well as a number of potential indications and uses associated with and beyond DED. These include dry eye associated with contact lens intolerance and ocular surface preparation for refractive surgeries. We have also developed and are evaluating OC-02 (simpanicline), in two Phase 2b clinical trials for DED. We believe that targeting the parasympathetic nervous system through the use of locally administered cholinergic agonists has the potential to treat a wide range of diseases and disorders.